We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Leap-In Transposase® Bundled With VIPS™ Single Cell Cloning Instrument for Cell Line Development
Product News

Leap-In Transposase® Bundled With VIPS™ Single Cell Cloning Instrument for Cell Line Development

Leap-In Transposase® Bundled With VIPS™ Single Cell Cloning Instrument for Cell Line Development
Product News

Leap-In Transposase® Bundled With VIPS™ Single Cell Cloning Instrument for Cell Line Development


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Leap-In Transposase® Bundled With VIPS™ Single Cell Cloning Instrument for Cell Line Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Solentim, a company specializing in cell line development (CLD) instrumentation, and bioengineering company ATUM, have announced that Solentim will bundle access to the Leap-In Transposase® platform together with the Solentim VIPS™ single cell cloning instrument. Leap-In Transposases enable stable high titer clones to be isolated whilst screening orders of magnitude fewer clones than alternative strategies. The VIPS seeding and clonality validation system is optimized to efficiently isolate and track each high expressing clone. This new commercial agreement will enable Solentim’s customers all over the world to readily access the Leap-In Transposase technology.

“This agreement further cements our partnership with ATUM,” explained Dr Ian Taylor, Chief Business Officer of Solentim. “Over the past few months, we have seen pharma customers receive the first IND approvals using Leap-In Transposase, giving confidence to other customers that Leap-In combined with the VIPS technology is a sound choice when implementing their commercial CLD workflow.”

“We have fully embraced the VIPS technology from Solentim within our own company and it has become a cornerstone of our cell line development process. Solentim has been an outstanding partner to work with and we look forward to expanding our commercial success for Leap-In using their strong brand in CLD and global routes to market” commented Dr Jeremy Minshull, CEO of ATUM.

Advertisement